Badanie nad skutecznością i bezpieczeństwem crinecerfont u dorosłych z klasycznym wrodzonym przerostem nadnerczy

Classic Congenital Adrenal Hyperplasia (CAH) is a genetic condition that affects the adrenal glands, which are responsible for producing important hormones. This study is focused on evaluating a new treatment called crinecerfont (also known by its code name NBI-74788) for adults with CAH. The purpose of the study is to see if crinecerfont can help reduce the amount of other medications, called glucocorticoids, that patients need to take while still keeping their hormone levels under control.

Participants in the study will receive either crinecerfont or a placebo, which looks like the medication but does not contain the active ingredient. The study will start with a period where neither the participants nor the researchers know who is receiving the actual medication or the placebo. After this initial phase, all participants will have the opportunity to receive crinecerfont. The study will monitor how well crinecerfont works in reducing the need for glucocorticoids and its effects on hormone levels over time.

The study will also assess the safety of crinecerfont and how well it is tolerated by participants. This involves checking for any side effects and measuring the levels of crinecerfont in the blood. The study aims to provide valuable information on whether crinecerfont can be a beneficial treatment option for managing Classic Congenital Adrenal Hyperplasia.